Stock Ratings / Health Care / CRMD / options

CLYM (38) IRWD (69) ACRS (31) NVCT (43) ⌘ Pro Terminal →

CorMedix Inc. (CRMD) Options Positioning, Max Pain & Unusual Sweeps

Q: What is CRMD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CRMD.

$7.64 -6.83% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

CorMedix Inc. (CRMD) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $595.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRMD)Realized 20D OHLCV Swing Band: ±11.4%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±11.4%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CRMD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CRMD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating CRMD & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on CRMD
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.66%▼ DESCENDING CHANNEL

2026-10-30O $7.68H $7.68L $5.63C $7.64VOL 7.01M

RES: $8.84SUP: $6.38SMA50: $7.80SMA200: $7.67

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRMD Butterfly Map → + Track CRMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-15.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRMD)

Health Care Rank #171 of 1016 ⚔️ CLYM vs CRMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRMD vs. CLYM, IRWD, ACRS, NVCT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CorMedix Inc. (CRMD) ranks #171 by composite RQD confidence (62/100, grade C) and #422 by equity capitalization ($595.5M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with CRMD at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRMD ACTIVE CorMedix Inc.	C	62/100	3.7x	88.5%	45.5%	-6.83%	$595.5M	Benchmark Subject
CLYM Climb Bio Inc.	D-	38/100	—	—	-35.0%	+2.08%	$593.3M	/clym-vs-crmd →
IRWD Ironwood Pharmaceuticals Inc. (Class A)	C+	69/100	24.9x	—	85.0%	+0.28%	$598.2M	/irwd-vs-crmd →
ACRS Aclaris Therapeutics Inc.	E	31/100	—	73.3%	-35.0%	+0.76%	$587.3M	/acrs-vs-crmd →
NVCT Nuvectis Pharma Inc.	D-	43/100	—	—	-35.0%	+1.14%	$605.6M	/nvct-vs-crmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001410098

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CorMedix Inc. (CRMD) reported GAAP revenue of $311.7M (+617.0% vs. FY2024 revenue of $43.5M ) , GAAP net income of $163.1M, operating cash flow of $175.0M, and free cash flow of $172.8M (+440.6% YoY). On the balance sheet, CRMD closed FY2025 with $826.1M in total assets against $0 in total debt (Altman Z-Score: 1.81, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$311.7M	$163.1M	$175.0M	$172.8M	$826.1M	—
FY2024 (FY)	2024-12-31	$43.5M	-$17.9M	-$50.6M	-$50.7M	$118.8M	—
FY2023 (FY)	2023-12-31	$0	-$46.3M	-$38.4M	-$38.4M	—	—

3. CRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CorMedix Inc. (NASDAQ: CRMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $7.64 (-6.83% 1D, market cap $595.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, CRMD ranks #171 in composite RQD confidence.

How does CRMD compare to CLYM and IRWD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRMD carries a Roarable C (62/100 RQD), trailing P/E of 3.7x, gross margin of 88.5%, and ROIC of 45.5%. By comparison, CLYM (Climb Bio Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $593.3M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C+ grade (69/100 RQD, P/E 24.9x, ROIC 85.0%, cap $598.2M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRMD?

Per CRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001410098), CorMedix Inc. generated $311.7M in revenue (+617.0% YoY), $163.1M in net income, and $172.8M in free cash flow against $826.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (89% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRMD trading relative to its 50-day, 200-day, and 52-week technical levels?

CRMD last traded at $7.64 (-6.83% on volume of 1,887,190 shares), positioning the stock -2.05% below its 50-day simple moving average ($7.80) and -0.39% below its 200-day simple moving average ($7.67). Across its 52-week range of $5.63 to $13.02, CRMD sits at the 27.2% percentile with a 14-day RSI of 25.3 (OVERSOLD (<32)) and an implied next-earnings move of ±11.4% ($6.77 to $8.51).

CRMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CRMD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CRMD.

Direct Sub-Reports: CRMD RQD Cockpit CRMD 12M Forecast CRMD Earnings & Move CRMD Dividends & DRIP CRMD Insiders & 13F CRMD Whale Options CRMD Profit Sankey CRMD News & Why